Transfer Factor Manufacturing via HPLC and Lyophilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for manufacturing transfer factor medicaments are inefficient in ensuring the normalization of donor immune systems and maintaining the therapeutic efficacy of biologically active low molecular substances, particularly in terms of molecular weight distribution and sterility, which affects the drug's effectiveness in immune-related therapies.
Innovation Solution
A method involving high-pressure liquid chromatography, moderate liquid chromatography, and specific manufacturing steps such as dialysis or ultrafiltration, followed by lyophilization, to produce a transfer factor medicament with a precise molecular weight distribution and sterility, ensuring the normalization of donor immune systems and amplification of therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If dialysis or ultrafiltration is used to obtain transfer factor, then the medicament can be produced, but the molecular weight distribution and sterility cannot be precisely controlled
Solution Approach 1:
The patent divides the manufacturing process into distinct stages: initial dialysis/ultrafiltration to obtain transfer factor, followed by high-pressure liquid chromatography (HPLC) for precise molecular weight separation, and moderate liquid chromatography for further purification. This segmentation allows each process to optimize for its specific function, achieving precise molecular weight distribution control while maintaining manageable process complexity through modular organization.
Solution Approach 2:
The patent introduces chromatography systems as intermediary purification stages between the initial dialysis/ultrafiltration and the final product. These intermediary processes act as mediators that selectively separate and purify transfer factor based on molecular weight, enabling precise control of the molecular weight distribution without requiring the initial dialysis process to achieve perfect separation alone.
2Manufacturing precision
If multiple chromatography steps are added to control molecular weight distribution, then manufacturing precision improves, but productivity decreases
Solution Approach 1:
The patent performs preliminary dialysis and ultrafiltration to concentrate and pre-purify the transfer factor before subjecting it to chromatography. This preliminary action reduces the volume and complexity of the sample entering the chromatography system, allowing faster chromatographic runs while maintaining high sterility control. The pre-concentration step ensures that the chromatography columns work with optimized samples, improving both precision and throughput.
Solution Approach 2:
The patent employs high-pressure liquid chromatography (HPLC) which uses high pressure as a key parameter change to accelerate the chromatographic process. By increasing the pressure, the mobile phase flows faster through the column, reducing analysis and purification time while maintaining or improving separation precision. This parameter change allows the system to achieve both high sterility control and improved manufacturing speed.
3Measurement precision
If high-pressure liquid chromatography is used for molecular profile determination, then measurement precision improves, but the manufacturing complexity increases
Solution Approach 1:
The patent uses high-pressure liquid chromatography (HPLC) system that serves multiple functions: it performs molecular profile determination, separates transfer factor by molecular weight, and can be integrated with the purification process. This multi-functionality allows the same sophisticated instrumentation to provide both analytical precision and manufacturing value, reducing the need for separate complex analytical and manufacturing systems.
Solution Approach 2:
The patent replaces traditional mechanical separation methods with high-pressure liquid chromatography, which uses pressure-driven fluid flow and molecular interactions with stationary phases to achieve separation. This substitution provides superior measurement precision for molecular profile analysis while the automated nature of HPLC reduces manual operational complexity compared to manual fractionation or centrifugation methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively normalizes donor immune systems, enhancing the therapeutic effects of the transfer factor by maintaining a specific molecular weight distribution and ensuring sterility, making it suitable for immune-related therapies and prophylactic use in various conditions.
Implementation Method 1
dialysis or ultrafiltration being the most frequent of them
Implementation Method 2
dialysis or ultrafiltration being the most frequent of them
Implementation Method 3
Molecular profile of transfer factor is determined by highly effective (high pressure) liquid chromatography
Implementation Method 4
The remedy is manufactured in a lyophilised form
Data Source
AI summary
The object of protection of the "Transfer Factor" medicament, its manufacturing and clinical use. The manufacturing includes: technological conditions of leucocytes concentrate preparation, its dialysis or ultrafiltration, concentration by lyophylisation, raw medicament solution preparation, sterilising filtration and termic inactivation and final lyophylisation. The technology of manufacturing should ensure standard preparation of stabile sterile medicament clinical use describes recommended therapeutic dosage of medicament. The therapeutic effect of transfer factor rests especially on normalisation of acceptor's immune system normalisation.